promo_leaderboard Ad
‹ All stocks
ALKS

Alkermes plc

ALKS · NASDAQ · Healthcare
$45.98
▼ $0.55 (-1.19%)
$40.10 $42.70 $45.29 $47.89 $45.98 Oct 18 Nov 02 Nov 17
Day range
$45.86 – $46.65
Year range
$27.00 – $55.67
Open
$46.37
Previous close
$46.53
Market cap
$7.73B
Volume (24h)
$39.9K
Volume (52w)
$1.84M
Performance
7D
▼ -1.06%
1M
▲ 7.00%
3M
▼ -8.38%
6M
▲ 24.43%
1Y
▲ 56.76%
YTD
▲ 62.69%
3Y
▲ 90.14%
5Y
▲ 96.99%
All-time
▲ 735.94%
Key statistics
P/E ratio
62.98
EPS (TTM)
$0.73
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
168.0M
About Alkermes plc

Alkermes plc is an Irish-headquartered biopharmaceutical firm, established in 1987, focused on the discovery, development, and commercialization of innovative pharmaceutical treatments. These efforts are directed at fulfilling critical unmet medical needs for patients across a range of therapeutic areas, both domestically and internationally. Its current portfolio of marketed products features ARISTADA for schizophrenia; VIVITROL, targeting alcohol dependence and preventing opioid dependence; and several medications for schizophrenia and bipolar I disorder, including RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA. Furthermore, VUMERITY is available for managing relapsing forms of multiple sclerosis in adults, encompassing clinically isolated syndrome, relapsing-remitting, and active secondary progressive diseases. The company is also actively developing new drug candidates, such as LYBALVI, an oral atypical antipsychotic for adults with schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered fusion protein designed to amplify tumor-killing immune cells while bypassing the activation of immunosuppressive cells. Alkermes maintains key strategic collaboration agreements, primarily with various entities under the Janssen Pharmaceutica umbrella.

Visit website
Country: United States of America
More in Healthcare